Breye Therapeutics ApS — Credit Rating and Financial Key Figures

Breye Therapeutics ApS (CVR number: 40279865) is a company from RUDERSDAL. The company recorded a gross profit of -7812.1 kDKK in 2023. The operating profit was -75.4 mDKK, while net earnings were -70.2 mDKK. The profitability of the company measured by Return on Assets (ROA) was -174.4 %, which can be considered poor and Return on Equity (ROE) was -222.7 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 79.9 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. Breye Therapeutics ApS's liquidity measured by quick ratio was 6.5 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.